Sarepta Therapeutics (SRPT) is back in focus after the FDA accepted supplemental New Drug Applications for AMONDYS 45 and VYONDYS 53, a regulatory update that could influence how investors assess the stock.

The FDA sNDA news comes after a weak stretch for Sarepta Therapeutics, with the share price down 21.78% over 90 days and the 3 year total shareholder return declining 85%. This indicates fading momentum despite the regulatory progress.

If you are looking beyond Sarepta Therapeutics in rare disease and biotech, this could be a useful moment to see what else is moving among 41 healthcare AI stocks

With Sarepta Therapeutics stock down sharply over three and five years and trading at US$17.02 against an analyst price target of US$22 and an indicated intrinsic discount of 75.73%, investors now face a key question: is this a genuine opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 21.4% Undervalued

The most followed narrative on Sarepta Therapeutics estimates a fair value of $21.65 per share versus the last close at $17.02. This frames the current price as meaningfully below that modelled level while highlighting a complex earnings path.

The analysts have a consensus price target of $21.65 for Sarepta Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $38.0, and the most bearish reporting a price target of just $5.0.

Analysts are working with falling revenues, a sharp swing in earnings and a richer future earnings multiple to justify that fair value. Want to see which revenue path, margin level and share count assumptions sit underneath this reset narrative and how they tie back to ELEVIDYS and the broader RNA pipeline?

Result: Fair Value of $21.65 (UNDERVALUED)

However, the Sarepta Therapeutics story could be knocked off course if ELEVIDYS safety concerns further weigh on demand or if administrative bottlenecks keep delaying gene therapy treatments.

Another View: Multiples Paint A Tougher Picture For Sarepta Therapeutics

The fair value narrative for Sarepta Therapeutics centers on discounted cash flows and analyst targets, but the current P/E ratio of 27.6x tells a tougher story. It sits above the US Biotechs industry average of 17.2x and well above the 6.4x fair ratio that our models suggest the market could move toward, which points to valuation risk if sentiment weakens.

For a closer look at how this P/E gap stacks up against peers and the fair ratio, and what that could mean for your own assumptions, have a look at the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment on Sarepta Therapeutics clearly mixed, this is a moment to move quickly, review the underlying data, and form your own view using the 2 key rewards and 2 important warning signs

Looking For More Investment Ideas Beyond Sarepta Therapeutics?

If Sarepta Therapeutics has you rethinking your watchlist, use this moment to broaden your opportunity set with focused screens built from real fundamentals.

• Target potential mispriced opportunities by checking companies that stand out as 42 high quality undervalued stocks based on earnings strength and balance sheet quality.
• Prioritize resilience first and chase returns second by filtering for 72 resilient stocks with low risk scores supported by robust financial profiles and fewer red flags.
• Spot future contenders early by scanning the screener containing 19 high quality undiscovered gems before the broader market starts paying attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.